- Home
- ELLO vs LRMR Comparison
ELLO vs LRMR Comparison
Compare ELLO & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- LRMR
- Stock Information
- Founded
- ELLO 1987
- LRMR N/A
- Country
- ELLO Israel
- LRMR United States
- Employees
- ELLO N/A
- LRMR N/A
- Industry
- ELLO Electric Utilities: Central
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- ELLO Utilities
- LRMR Health Care
- Exchange
- ELLO Nasdaq
- LRMR Nasdaq
- Market Cap
- ELLO 232.0M
- LRMR 204.9M
- IPO Year
- ELLO 1995
- LRMR N/A
- Fundamental
- Price
- ELLO $18.06
- LRMR $3.58
- Analyst Decision
- ELLO
- LRMR Strong Buy
- Analyst Count
- ELLO 0
- LRMR 7
- Target Price
- ELLO N/A
- LRMR $17.86
- AVG Volume (30 Days)
- ELLO 9.3K
- LRMR 1.6M
- Earning Date
- ELLO 09-29-2025
- LRMR 08-19-2025
- Dividend Yield
- ELLO N/A
- LRMR N/A
- EPS Growth
- ELLO N/A
- LRMR N/A
- EPS
- ELLO 0.43
- LRMR N/A
- Revenue
- ELLO $44,405,534.00
- LRMR N/A
- Revenue This Year
- ELLO N/A
- LRMR N/A
- Revenue Next Year
- ELLO N/A
- LRMR N/A
- P/E Ratio
- ELLO $46.92
- LRMR N/A
- Revenue Growth
- ELLO N/A
- LRMR N/A
- 52 Week Low
- ELLO $11.30
- LRMR $1.61
- 52 Week High
- ELLO $20.81
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- ELLO 56.56
- LRMR 55.11
- Support Level
- ELLO $17.05
- LRMR $3.51
- Resistance Level
- ELLO $19.40
- LRMR $3.97
- Average True Range (ATR)
- ELLO 0.64
- LRMR 0.35
- MACD
- ELLO -0.04
- LRMR -0.02
- Stochastic Oscillator
- ELLO 34.75
- LRMR 38.57
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.